Cargando…

Commentary: Management Strategies for POSEIDON Groups 3 and 4

Detalles Bibliográficos
Autor principal:	Bühler, Klaus F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992565/ https://www.ncbi.nlm.nih.gov/pubmed/32038485 http://dx.doi.org/10.3389/fendo.2019.00920

Ejemplares similares

Commentary: Management Strategies for POSEIDON Groups 3 and 4
por: Fischer, Robert, et al.
Publicado: (2020)

Management Strategies for POSEIDON Groups 3 and 4
por: Haahr, Thor, et al.
Publicado: (2019)

Management Strategies for POSEIDON Group 2
por: Sunkara, Sesh Kamal, et al.
Publicado: (2020)

Management Strategies for POSEIDON's Group 1
por: Polyzos, Nikolaos P., et al.
Publicado: (2019)

The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists
por: Esteves, Sandro C., et al.
Publicado: (2019)

Future Perspectives of POSEIDON Stratification for Clinical Practice and Research
por: Humaidan, Peter, et al.
Publicado: (2019)

Co-Administration of Clomiphene Citrate and Letrozole in Mild Ovarian Stimulation Versus Conventional Controlled Ovarian Stimulation Among POSEIDON Group 4 Patients
por: Lin, Hsin-Ta, et al.
Publicado: (2022)

Ovarian Reserve Markers to Identify Poor Responders in the Context of Poseidon Classification
por: Grisendi, Valentina, et al.
Publicado: (2019)

Understanding Follicular Output Rate (FORT) and its Implications for POSEIDON Criteria
por: Grynberg, Michael, et al.
Publicado: (2019)

Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines
por: Esteves, Sandro C., et al.
Publicado: (2021)

Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria
por: Liu, Xueying, et al.
Publicado: (2021)

Editorial: POSEIDON’s Stratification of ‘Low Prognosis’ Patients in ART: The WHY, the WHAT, and the HOW
por: Esteves, Sandro C., et al.
Publicado: (2021)

Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria—The Why
por: Esteves, Sandro C., et al.
Publicado: (2018)

The Livebirth Rate Per In Vitro Fertilization Cycle Is Higher Than The Cumulative Live Birth Rates of Intrauterine Insemination for Patients of Poseidon Group 3 With Unexplained Infertility
por: Wu, Yixuan, et al.
Publicado: (2021)

An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria
por: Levi-Setti, Paolo Emanuele, et al.
Publicado: (2019)

Comparison between the modified long gonadotropin-releasing hormone agonist protocol and the non-downregulation protocol in POSEIDON groups: a propensity score matching retrospective cohort study
por: Chen, Chunyan, et al.
Publicado: (2023)

Androgens Profile in Blood Serum and Follicular Fluid of Women With Poor Ovarian Response During Controlled Ovarian Stimulation Reveals Differences Amongst POSEIDON Stratification Groups: A Pilot Study
por: Fuentes, Ariel, et al.
Publicado: (2019)

Low Prognosis by the POSEIDON Criteria in Women Undergoing Assisted Reproductive Technology: A Multicenter and Multinational Prevalence Study of Over 13,000 Patients
por: Esteves, Sandro C., et al.
Publicado: (2021)

The Role of Traditional Chinese Formula Ding-Kun Pill (DKP) in Expected Poor Ovarian Response Women (POSEIDON Group 4) Undergoing In Vitro Fertilization-Embryo Transfer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Song, Jing-Yan, et al.
Publicado: (2021)

Predictive Factors for Live Birth in Fresh In Vitro Fertilization/Intracytoplasmic Sperm Injection Treatment in Poor Ovarian Reserve Patients Classified by the POSEIDON Criteria
por: Li, Fei, et al.
Publicado: (2021)

Cumulative live birth rates and birth outcomes after IVF/ICSI treatment cycles in young POSEIDON patients: A real-world study
por: Yan, Enqi, et al.
Publicado: (2023)

Cumulative Live Birth Rates of Good and Low Prognosis Patients According to POSEIDON Criteria: A Single Center Analysis of 18,455 Treatment Cycles
por: Shi, Wenhao, et al.
Publicado: (2019)

Cumulative Live Birth Rates in Low Prognosis Patients According to the POSEIDON Criteria: An Analysis of 26,697 Cycles of in vitro Fertilization/Intracytoplasmic Sperm Injection
por: Li, Yuan, et al.
Publicado: (2019)

Comparison of Cumulative Live Birth Rates Between GnRH-A and PPOS in Low-Prognosis Patients According to POSEIDON Criteria: A Cohort Study
por: Zhang, Shaodi, et al.
Publicado: (2021)

Follicular Output Rate and Follicle-to-Oocyte Index of Low Prognosis Patients According to POSEIDON Criteria: A Retrospective Cohort Study of 32,128 Treatment Cycles
por: Chen, Lijuan, et al.
Publicado: (2020)

The Effect of Growth Hormone on the Clinical Outcomes of Poor Ovarian Reserve Patients Undergoing in vitro Fertilization/Intracytoplasmic Sperm Injection Treatment: A Retrospective Study Based on POSEIDON Criteria
por: Cai, Mei-hong, et al.
Publicado: (2019)

POSEIDON: The secrets of the Trident Node monitoring tool
por: Kuffo Rivero, Leonardo Xavier
Publicado: (2018)

Comparative Effectiveness of Mild or Conventional GnRH-Antagonist Protocols for Ovarian Stimulation in Poor Responders (Poseidon Group 4)
por: Le, Hoang, et al.
Publicado: (2020)

Commentary: L-T4 Therapy in Enteric Malabsorptive Disorders
por: Giuffrida, Giuseppe, et al.
Publicado: (2021)

A propensity score matching comparison between GnRH agonist and GnRH antagonist protocols in patients in POSEIDON groups 3 and 4
por: Tan, Jifan, et al.
Publicado: (2023)

Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept
por: Drakopoulos, Panagiotis, et al.
Publicado: (2020)

Dual stimulation in unexpected poor responder POSEIDON classification group 1, sub–group 2a: A cross-sectional study
por: Eftekhar, Maryam, et al.
Publicado: (2020)

Principles of open source bioinstrumentation applied to the poseidon syringe pump system
por: Booeshaghi, A. Sina, et al.
Publicado: (2019)

Reply: The low responder according to the POSEIDON criteria: is the prognosis really poor?
por: Leijdekkers, Jori A, et al.
Publicado: (2019)

The POSEIDON stratification - moving from poor ovarian response to low prognosis
por: Roque, Matheus, et al.
Publicado: (2021)

Commentary: 3-Iodothyronamine Reduces Insulin Secretion In Vitro via a Mitochondrial Mechanism
por: Laurino, Annunziatina, et al.
Publicado: (2018)

Commentary: Molecular Mechanisms of Action of FSH
por: Cannarella, Rossella, et al.
Publicado: (2019)

Commentary: Torpor: The Rise and Fall of 3-Monoiodothyronamine from Brain to Gut—From Gut to Brain?
por: Laurino, Annunziatina, et al.
Publicado: (2017)

Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management
por: Fanciulli, Giuseppe, et al.
Publicado: (2021)

The POSEIDON-R compartment model for the prediction of transport and fate of radionuclides in the marine environment
por: Maderich, V., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_luv1iq0nmbumhpcln087eu0tia